Stock Market News for October 8, 2026

At a glance

On October 8, 2026, Crescent Energy Company agreed to buy Devon Energy’s Eagle Ford assets for approximately $3.85 billion and launched a $1 billion public offering; Pacira BioSciences agreed to be acquired by Viatris for $36.50 per share; ADC Therapeutics announced an $86.6 million private placement and amendments; argenx reported positive Phase 2 FB102 topline results and separately discontinued a Phase 3 UNITY study for futility.

Deals and acquisitions

Crescent Energy Company (CRGY) signed a definitive agreement to acquire Devon Energy’s Eagle Ford assets for an estimated net price of approximately $3.85 billion, with closing expected in Q4 2026 or early 2027.

Crescent Energy Company (CRGY) announces public offering of Class A common stock of $1 billion to help fund the Eagle Ford asset acquisition; the offering is not contingent on the acquisition closing.

Pacira BioSciences (PCRX) agreed to be acquired by Viatris through a tender offer at $36.50 per share in cash, valuing Pacira’s equity at $1.65 billion, with closing expected by the end of 2026.

ADC Therapeutics (ADCT) announced an $86.6 million private placement and royalty and loan amendments intended to extend its expected cash runway into 2029; closing is expected October 22, 2026.

FTAI Aviation (FTAI) announced a multi-year engine exchange agreement with United Airlines expanding the program to designated CFM56-7B engines, starting with an initial group in 2026 and structured to expand as engines come due for removal.

Drug trials and regulatory

argenx (ARGX) announced positive topline results from a Phase 2 study of FB102 in adults with celiac disease, saying the trial met its primary endpoint on change in villus height-to-crypt depth ratio at day 78 (p=0.0176) and plans to advance FB102 into Phase 3.

argenx (ARGX) will discontinue its Phase 3 UNITY study of subcutaneous efgartigimod in moderate-to-severe Sjögren's disease after an Independent Data Monitoring Committee recommended stopping for futility following an interim analysis.

Biohaven (BHVN) entered an exclusive regional licensing agreement with Ono Pharmaceutical for its extracellular IgG degrader portfolio, receiving $80 million upfront and up to a conditional $20 million additional milestone payment.

Financings and offerings

Atrium Therapeutics (RNA) entered into a securities purchase agreement for a private placement expected to raise approximately $50 million in gross proceeds, with closing expected on or about October 9, 2026.

DarkIris (DKI) announced pricing of a best-efforts public offering expected to raise approximately $6 million, consisting of 4,166,666 units at $1.44 each, with warrants immediately exercisable and six-month expirations.

Energy and resources

National Energy Services Reunited (NESR) signed an agreement with Aramco for a lithium demonstration project valued at approximately $200 million, targeting 2,000 tons per annum of battery-grade lithium carbonate with commissioning planned for late 2027.

FIRST MAJESTIC SILVER (AG) reported third-quarter 2026 silver production of 3.4 million ounces and renewed a share repurchase program permitting purchases of up to 10,000,000 shares (about 2% of outstanding).

ChipMOS TECHNOLOGIES (IMOS) reported record-high Q3 2026 unaudited consolidated revenue of NT$8,400.8 million (US$263.8 million), up 36.7% year over year, citing sustained AI-related demand.

Company results and guidance

Helen Of Troy (HELE) reported fiscal 2027 second-quarter net sales of $440.9 million, GAAP net income of $4.6 million, diluted EPS of $0.19, and adjusted diluted EPS of $0.79, with gross margin at 52.2%.

Swvl Holdings (SWVL) reported first-half 2026 revenue of $16.2 million, up 59% year over year, with GCC revenue up 107% to $7.1 million and net dollar retention of 123%.

NOVAGOLD (NG) filed its third-quarter 2026 report showing a $36.0 million net loss for the quarter and approximately $343.4 million in cash and term deposits while advancing an all-share transaction to acquire Paulson’s remaining 40% interest in Donlin Gold.

Technology and product launches

Illumina (ILMN) released SpliceAI2, a genomic AI model that in matched Genomics England cohorts identified 17% more disease-relevant splice variants than other models in a newly released preprint.

QuantumScape (QS) introduced QS PowerBlock, a modular in-rack energy storage reference design for AI data centers claiming 4x the power density and 5x the runtime versus Open Rack V3 in prototype testing and modeled configurations.

First Breach (FBDT) announced an expanded recruitment initiative to support increased ammunition production and planned drone manufacturing operations in Hagerstown, Maryland.

Other notable news

Zhibao Technology (ZBAO) will proceed with a 1-for-50 reverse stock split of its Class A ordinary shares expected to take effect on October 12, 2026, with post-split trading to begin at market open that day.